Results from three new clinical trials suggest that treatment with PARP inhibitors might benefit women who are newly diagnosed with advanced ovarian cancer. In all three studies, the use of a PARP inhibitor, as first-line therapy, maintenance therapy, or both, substantially delayed the length of time before the women’s cancers came back or got worse.
A new analysis from the TAILORx randomized clinical trial shows that women with early-stage breast cancer and high recurrence scores on the Oncotype DX test who received chemotherapy with hormone therapy had better long-term outcomes than what would be expected from hormone therapy alone.
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.
TMIST (Tomosynthesis Mammographic Imaging Screening Trial) is a randomized breast screening trial that will help researchers learn about the best ways to find breast cancer in women who have no symptoms. The study compares two types of digital mammography: 2-D and 3-D. This page explains why this trial is important, who can take part, and how to enroll.
In a series of Twitter posts, NCI’s Center for Cancer Research (CCR) shares the story of Samantha Seinfeld, a metastatic breast cancer survivor who participated in a CCR first-in-human clinical trial over 10 years ago. Since then, she has remained cancer-free.
Clinical Trials Information for Patients and Caregivers
Taking part in a cancer treatment clinical trial is a big decision. This page presents a list of questions you may want to ask your doctor before deciding to participate in a clinical trial.
This phase 2 trial will test the antibiotic drug vancomycin in patients with fibrolamellar hepatocellular carcinoma (FLC) that cannot be treated surgically. FLC is a rare liver cancer that usually grows in teens and young adults. Doctors want to see if oral vancomycin is safe at a dose higher than that given for a bacterial infection and whether it has a beneficial effect on unresectable FLC.
This phase 3 trial will compare stereotactic radiosurgery given as a single treatment versus as multiple treatments over the course of several days (i.e., fractionated stereotactic radiosurgery) in patients that have had metastatic tumors surgically removed from the brain. Doctors want to find out if fractionated stereotactic radiosurgery is better or worse for these patients than the usual approach with single fraction stereotactic radiosurgery.
